Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall St set for lower open as Middle East clashes revive rate-hike speculation
- The Warsh pivot markets didn't expect
- Oil rises over 2% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
- GameStop posts higher income despite revenue drop in Q2 2026
- At least eight die, 18 missing after ferry capsizes off North Cyprus
- Manhunt underway after woman killed, several injured at Swiss rave shooting
- Aon close to acquiring USI Insurance from KKR in $17 billion deal, WSJ reports
- RedHill sells Talicia to Apotex for $18M upfront plus milestones
Autolus Therapeutics (AUTL) Announces Proposed Public Offering in the United States
December 8, 2022 4:04 PM ESTAutolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has commenced an underwritten public offering of American Depositary Shares (ADSs), each ADS representing one ordinary share. All ADSs to be sold in the proposed... More
Autolus Therapeutics (AUTL) to Receive $70 Million in Milestone Payments from Blackstone Life Sciences
December 8, 2022 4:03 PM ESTAutolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that Blackstone Life Sciences (Blackstone) has committed to make two pre-agreed milestone payments of $35m each to Autolus, totaling $70m. The milestones are expected to be recognized in Autolus Q4 2022 cash balance.
The first Blackstone milestone of $35m is being paid earlier than anticipated as a result of the joint steering committees review of Autolus interim analysis of pivotal FELIX Phase 2... More
